Glucose transporters in health and disease: from molecular mechanisms to therapeutic applications

The purpose of this review is to provide a comprehensive analysis of glucose transporters, integrating molecular mechanisms, physiological roles, and therapeutic applications across health and disease states. Glucose transport across cellular membranes, mediated by facilitative glucose transporters (GLUTs) and sodium-glucose cotransporters (SGLTs), represents a fundamental control point in glucose homeostasis. Since the initial discovery of specific membrane components for glucose transfer in 1948, our understanding has evolved substantially, revealing complex tissue-specific expression patterns and regulatory mechanisms. Recent structural biology advances, genetic studies, and clinical developments, particularly the success of SGLT2 inhibitors in treating type 2 diabetes and their unexpected benefits in heart failure and chronic kidney disease, have transformed our understanding of these essential proteins. This review examines the structural and functional properties of glucose transporters, their tissue-specific distribution and regulation, their roles in metabolic organs, and their dysfunction in various diseases. We specifically address unresolved questions regarding tissue-specific regulation, expanding roles in disease pathogenesis beyond diabetes, and emerging therapeutic strategies. By synthesizing recent technological advances, clinical implications, and areas of continuing controversy, this review provides a framework for understanding both the fundamental biology of glucose transporters and their growing therapeutic significance in metabolic diseases.

Authors

Institutions

Publication Details

Journal
Metabolism and Target Organ Damage
Published
2026-11-04
DOI
https://doi.org/10.20517/mtod.2025.151
Primary Topic
Metabolism, Diabetes, and Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glucose transporters in health and disease: from molecular mechanisms to therapeutic applications

Chiara Saponaro, John Griffith Jones, Isaline Louvet, Caroline Bonner et al.
Metabolism and Target Organ Damage
Metabolism, Diabetes, and Cancer
article

Glucose transporters in health and disease: from molecular mechanisms to therapeutic applications

Chiara Saponaro, John Griffith Jones, Isaline Louvet, Caroline Bonner, Maria Moreno Lopez
article en

Abstract

The purpose of this review is to provide a comprehensive analysis of glucose transporters, integrating molecular mechanisms, physiological roles, and therapeutic applications across health and disease states. Glucose transport across cellular membranes, mediated by facilitative glucose transporters (GLUTs) and sodium-glucose cotransporters (SGLTs), represents a fundamental control point in glucose homeostasis. Since the initial discovery of specific membrane components for glucose transfer in 1948, our understanding has evolved substantially, revealing complex tissue-specific expression patterns and regulatory mechanisms. Recent structural biology advances, genetic studies, and clinical developments, particularly the success of SGLT2 inhibitors in treating type 2 diabetes and their unexpected benefits in heart failure and chronic kidney disease, have transformed our understanding of these essential proteins. This review examines the structural and functional properties of glucose transporters, their tissue-specific distribution and regulation, their roles in metabolic organs, and their dysfunction in various diseases. We specifically address unresolved questions regarding tissue-specific regulation, expanding roles in disease pathogenesis beyond diabetes, and emerging therapeutic strategies. By synthesizing recent technological advances, clinical implications, and areas of continuing controversy, this review provides a framework for understanding both the fundamental biology of glucose transporters and their growing therapeutic significance in metabolic diseases.

Metabolism and Target Organ DamageVol. 6(4)
Inserm (FR), Université de Lille (FR), Institut Pasteur de Lille (FR), Centre Hospitalier Universitaire de Lille (FR), European Genomic Institute for Diabetes (FR), Recherche translationnelle sur le diabète et les troubles métaboliques (FR)
Openalex Percentile: Top 24%
Metabolism, Diabetes, and Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon